Radius Recycling 10-Q 12 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 12, 2014
Document and Entity Information	'	'
Entity Registrant Name	'Radius Health, Inc.	'
Entity Central Index Key	'0001428522	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	29,746,629
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$48,371	$12,303
Marketable securities	30,650	'
Prepaid expenses and other current assets	1,797	334
Total current assets	80,818	12,637
Property and equipment, net	70	76
Other assets	242	45
Total assets	81,130	12,758
Current liabilities:	'	'
Accounts payable	1,188	300
Accrued expenses and other current liabilities	19,895	22,007
Current portion of note payable, net of discount	'	13,005
Total current liabilities	21,083	35,312
Note payable, net of current portion and discount	20,299	'
Warrant liability	'	1,945
Commitments and contingencies	'	'
Stockholders' equity (deficit):	'	'
Common stock, $.0001 par value; 200,000,000 shares and 100,000,000 authorized, 29,726,194 shares and 385,664 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	3	'
Additional paid-in-capital	348,600	'
Accumulated other comprehensive income	1	'
Accumulated deficit	-308,856	-277,301
Total stockholders' equity (deficit)	39,748	-277,301
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	81,130	12,758
Series B Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	43,892
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	43,892
Series A-1 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	78,737
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	78,737
Series A-2 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	93,977
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	93,977
Series A-3 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	12,232
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	12,232
Series A-4 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	271
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	271
Series A-5 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	525
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	525
Series A-6 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	'	23,168
Stockholders' equity (deficit):	'	'
Total stockholders' equity (deficit)	'	$23,168

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	100,000,000
Common stock, shares issued	29,726,194	385,664
Common stock, shares outstanding	29,726,194	385,664
Series B-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	655,000
Preferred Stock, shares issued	'	0
Preferred Stock, shares outstanding	0	0
Series B Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	980,000
Preferred Stock, shares issued	0	701,235
Preferred Stock, shares outstanding	0	701,235
Series A-1 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	1,000,000
Preferred Stock, shares issued	0	939,612
Preferred Stock, shares outstanding	0	939,612
Series A-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	983,213
Preferred Stock, shares issued	0	983,208
Preferred Stock, shares outstanding	0	983,208
Series A-3 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	142,230
Preferred Stock, shares issued	0	142,227
Preferred Stock, shares outstanding	0	142,227
Series A-4 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	4,000
Preferred Stock, shares issued	0	3,998
Preferred Stock, shares outstanding	0	3,998
Series A-5 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	7,000
Preferred Stock, shares issued	0	6,443
Preferred Stock, shares outstanding	0	6,443
Series A-6 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	0	800,000
Preferred Stock, shares issued	0	496,111
Preferred Stock, shares outstanding	0	496,111

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
OPERATING EXPENSES:	'	'	'	'
Research and development	$10,618	$16,240	$20,335	$33,527
General and administrative	3,070	1,444	5,209	3,022
Loss from operations	-13,688	-17,684	-25,544	-36,549
OTHER (EXPENSE) INCOME:	'	'	'	'
Other income (expense) , net	1,727	-1,184	-506	10,072
Loss on retirement of note payable	-203	'	-203	'
Interest income	5	14	7	16
Interest expense	-450	-658	-851	-1,356
NET LOSS	-12,609	-19,512	-27,097	-27,817
OTHER COMPREHENSIVE LOSS, NET OF TAX:	'	'	'	'
Unrealized gain from marketable securities	1	3	1	3
COMPREHENSIVE LOSS	-12,608	-19,509	-27,096	-27,814
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 11):	($16,640)	($23,880)	($36,097)	($35,767)
LOSS PER SHARE:	'	'	'	'
Basic (in dollars per share)	($2.22)	($62.59)	($9.11)	($93.89)
Diluted (in dollars per share)	($2.22)	($62.59)	($9.11)	($93.89)
WEIGHTED AVERAGE SHARES:	'	'	'	'
Basic (in shares)	7,500,148	381,525	3,962,559	380,942
Diluted (in shares)	7,500,148	381,525	3,962,559	380,942

Statements_of_Convertible_Pref

Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)

Total

Common Stock

Additional Paid-In-Capital

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit

Series B-2 Convertible Preferred Stock

Series B Convertible Preferred Stock

Series A-1 Convertible Preferred Stock

Series A-2 Convertible Preferred Stock

Series A-3 Convertible Preferred Stock

Series A-4 Convertible Preferred Stock

Series A-5 Convertible Preferred Stock

Series A-6 Convertible Preferred Stock

In Thousands, except Share data, unless otherwise specified

Balance at Dec. 31, 2013

($277,301)

'

'

'

($277,301)

'

$43,892

$78,737

$93,977

$12,232

$271

$525

$23,168

Balance (in shares) at Dec. 31, 2013

'

385,664

'

'

'

'

701,235

939,612

983,208

142,227

3,998

6,443

496,111

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-27,097

'

'

'

-27,097

'

'

'

'

'

'

'

'

Unrealized gain from available-for-sale securities

1

'

'

1

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

'

26,152

'

'

'

'

'

'

10,109

Issuance of preferred stock (in shares)

'

'

'

'

'

448,060

'

'

'

'

'

'

186,847

Accretion of dividends on preferred stock

-9,000

'

-4,542

'

-4,458

685

1,515

3,084

3,246

470

'

'

'

Stock-based compensation expense

1,815

'

1,815

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net

50,150

1

50,149

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net (in shares)

'

7,012,744

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock into common stock

298,063

2

298,061

'

'

-26,837

-45,407

-81,821

-97,223

-12,702

-271

-525

-33,277

Conversion of convertible preferred stock, and associated accumulated dividends into common stock (in shares)

'

22,327,786

'

'

'

-448,060

-701,235

-939,612

-983,208

-142,227

-3,998

-6,443

-682,958

Reclassification of warrants liability to additional paid-in-capital

3,117

'

3,117

'

'

'

'

'

'

'

'

'

'

Balance at Jun. 30, 2014

$39,748

$3

$348,600

$1

($308,856)

'

'

'

'

'

'

'

'

Balance (in shares) at Jun. 30, 2014

'

29,726,194

'

'

'

'

'

'

'

'

'

'

'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS USED IN OPERATING ACTIVITIES:	'	'
Net loss	($27,097)	($27,817)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	33	13
Amortization of premium (accretion of discount) on marketable securities, net	'	14
Stock-based compensation expense	1,815	785
Research and development expense settled in stock	2,717	7,255
Change in fair value of other current assets, warrant liability and other liability	505	-10,074
Non-cash interest	127	215
Non-cash portion of loss on retirement of note payable	57	'
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-1,420	647
Other long-term assets	-150	'
Accounts payable	888	1,018
Accrued expenses and other current liabilities	3,254	8,240
Net cash used in operating activities	-19,271	-19,704
CASH FLOWS USED IN INVESTING ACTIVITIES:	'	'
Purchases of property and equipment	-29	'
Purchases of marketable securities	-30,649	-17,070
Sales and maturities of marketable securities	'	4,000
Net cash used in investing activities	-30,678	-13,070
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:	'	'
Proceeds from exercise of stock options	'	13
Proceeds from note payable, net	20,568	'
Payments on note payable	-13,156	-3,938
Proceeds from the issuance of common stock, net	51,332	'
Deferred financing costs	-95	'
Proceeds from the issuance of preferred stock, net	27,368	42,870
Net cash provided by financing activities	86,017	38,945
NET INCREASE IN CASH AND CASH EQUIVALENTS	36,068	6,171
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	12,303	18,653
CASH AND CASH EQUIVALENTS AT END OF PERIOD	48,371	24,824
SUPPLEMENTAL DISCLOSURES:	'	'
Cash paid for interest	555	998
NON-CASH FINANCING ACTIVITIES:	'	'
Accretion of dividends on preferred stock	9,000	7,950
Fair value of Series A-6 convertible preferred stock issued as settlement of liability	10,109	'
Fair value of warrants issued	1,511	1,356
Initial public offering costs included in accrued expenses and other current liabilities	1,182	'
Reclassification of preferred stock to common stock	$298,063	'

Organization

Organization	6 Months Ended
	Jun. 30, 2014
Organization	'
Organization	'
	1. Organization
	Radius Health, Inc. (“Radius” or the “Company”), which was formerly known as MPM Acquisition Corp., is a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058), a bone anabolic for the treatment of osteoporosis delivered via subcutaneous injection, which the Company refers to as Abaloparatide-SC. The Company is currently in Phase 3 development of Abaloparatide-SC and expects to announce top-line data from this study in late 2014. If the results are positive, the Company plans to submit a new drug application in the United States, and a marketing authorization application in Europe in mid-2015. The Company holds worldwide commercialization rights to Abaloparatide-SC, other than in Japan, and with a favorable regulatory outcome, anticipates its first commercial sales of Abaloparatide-SC will take place in 2016. The Company is leveraging its investment in Abaloparatide-SC to develop Abaloparatide-TD. The Company expects this line extension will provide improved patient convenience by enabling administration of abaloparatide through a short-wear-time transdermal patch. The Company has recently completed a successful Phase 2 proof of concept study of Abaloparatide-TD.
	The Company’s current clinical product portfolio also includes a novel oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader (“SERD”). The Company is developing RAD1901 at higher doses, for the treatment of metastatic breast cancer, including breast cancer brain metastases (“BCBM”).  At lower doses RAD1901 acts as a selective estrogen-receptor modulator (“SERM”).  Low-dose RAD1901 has shown efficacy for the treatment of vasomotor symptoms such as hot flashes in a successful Phase 2 clinical trial. In 2014, the Company expects to commence a Phase 1 clinical trial to evaluate RAD1901 for the treatment of metastatic breast cancer.
	Pursuant to an Agreement and Plan of Merger (the “Merger Agreement” or the “Merger”) entered into in April 2011 by and among the Company (a public-reporting, Form 10 shell company at the time), RHI Merger Corp., a Delaware corporation and wholly owned subsidiary of the Company (“MergerCo”), and Radius Health, Inc., a privately-held Delaware corporation (“Former Operating Company”), MergerCo merged with and into the Former Operating Company, with the Former Operating Company remaining as the surviving entity and a wholly-owned subsidiary of the Company. This transaction is herein referred to as the “Merger”. The Merger was effective as of May 17, 2011, upon the filing of a certificate of merger with the Delaware Secretary of State. Following the Merger on May 17, 2011, the Company’s Board of Directors approved a transaction pursuant to which the Former Operating Company merged with and into the Company, leaving the Company as the surviving corporation (the “Short-Form Merger”). As part of the Short-Form Merger, the Company, then named MPM Acquisition Corp., changed its name to Radius Health, Inc. and assumed the operations of the Former Operating Company.
	The Company is subject to the risks associated with emerging companies with a limited operating history, including dependence on key individuals, a developing business model, market acceptance of the Company’s product candidates, competition for its product candidates, and the continued ability to obtain adequate financing to fund the Company’s future operations. The Company has incurred losses and expects to continue to incur additional losses for the foreseeable future. As of June 30, 2014, the Company had an accumulated deficit of $308.9 million and believes that its existing cash, cash equivalents and marketable securities at June 30, 2014, will be sufficient to fund its operations into the third quarter of 2015.  Accordingly, the Company expects to pursue additional financing opportunities to address its capital needs, including the completion of a private placement or public offering and other strategic financing alternatives that could include, but are not limited to, partnering or other collaboration agreements.  However, there is no guarantee that any of these financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical and clinical trials and obtain approval of any product candidates from the U.S. Food and Drug Administration or other regulatory authorities. In addition, the Company could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or discontinue operations entirely.

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Basis of Presentation and Significant Accounting Policies	'
Basis of Presentation and Significant Accounting Policies	'
	2. Basis of Presentation and Significant Accounting Policies
	Basis of Presentation—The accompanying unaudited condensed financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.
	When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2014. Subsequent events have been evaluated up to the date of issuance of these financials. For further information, refer to the financial statements and footnotes included in the Company’s audited financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K/A, as filed with the Securities and Exchange Commission on April 3, 2014.
	Significant Accounting Policies—The significant accounting policies identified in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2013 relate to research and development costs, stock-based compensation, fair value measures, property and equipment, license agreements, impairment of long-lived assets and income taxes. There were no changes to significant accounting policies during the six months ended June 30, 2014.
	Initial Public Offering-On June 11, 2014, the Company completed its initial public offering whereby the Company sold 6,500,000 shares of common stock at a price of $8.00 per share. The shares began trading on the NASDAQ Global Market on June 6, 2014. In connection with the offering, all outstanding shares of our convertible preferred stock converted into 19,465,132 shares of common stock and 2,862,654 shares of common stock were issued in satisfaction of accumulated dividends accrued on the preferred stock. In addition, all outstanding warrants to purchase shares of A-1 convertible preferred stock and warrants to purchase shares of series B-2 convertible preferred stock were converted into the right to purchase 149,452 shares of common stock and the Company’s warrant liability was reclassified to equity.
	On June 18, 2014 and June 25, 2014, the underwriters purchased an additional 512,744 shares in the aggregate by exercising a portion of the over-allotment option granted to them in connection with the initial public offering.  As a result of the closing of the initial public offering and subsequent exercise of the over-allotment option, the Company received aggregate proceeds, net of underwriting discounts, commissions and offering costs, of approximately $50.2 million.
	In connection with the completion of its initial public offering, the Company filed an amended and restated certificate of incorporation, which, among other things, changed the number of authorized shares of common stock to 200,000,000 shares.
	Reverse Stock Split— On April 24, 2014, the Company effected a reverse stock split of the Company’s common stock. The number of authorized shares of the Company’s common stock and the par value did not change.  Pursuant to the stock split, every 2.28 shares of the Company’s issued and outstanding common stock were automatically combined into one issued and outstanding share of the Company’s common stock. All shares and per share amounts in the condensed financial statements and accompanying notes have been retroactively adjusted to give effect to the reverse stock split.
	Recently Adopted Accounting Standards—In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 were effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company adopted ASU 2013-11 on January 1, 2014.  Its adoption did not have a material impact on the Company’s results of operations, financial position, or cash flows.
	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity (“ASU 2013-12”). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. The Company adopted ASU 2013-12 on January 1, 2014.  Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	3. Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Research costs - Nordic (1)	$	14,083	$	17,998
	Research costs - other	2,327		1,599
	Payroll and employee benefits	932		1,005
	Professional fees	2,208		426
	Vacation	119		69
	Interest on notes payable	205		852
	Other	21		58
	Total accrued expenses and other current liabilities	$	19,895	$	22,007
	(1)     Includes amounts accrued ratably over the estimated per patient treatment period under the Nordic Work Statement NB-1 and Work Statement NB-3.  Amounts do not include pass-through costs which are expensed as incurred or upon delivery.  See note 9 for additional information.

Loan_and_Security_Agreement

Loan and Security Agreement	6 Months Ended
	Jun. 30, 2014
Loan and Security Agreement	'
Loan and Security Agreement	'
	4.  Loan and Security Agreement
	On May 30, 2014, the Company entered into a Loan and Security Agreement (the “New Credit Facility), with Solar Capital Ltd. (“Solar”), as collateral agent and a lender, and Oxford Finance LLC (“Oxford), as a lender (the “Lenders”), pursuant to which Solar and Oxford agreed to make available to the Company $30.0 million in the aggregate subject to certain conditions to funding. An initial term loan was made on May 30, 2014 in an aggregate principal amount equal to $21.0 million (“Initial Term Loan”).
	The Company is required to make interest-only payments through June 1, 2015, and beginning on July 1, 2015, it is required to make payments of principal and accrued interest in equal monthly installments over a term of 36 months. If the Company consummates any one or more public or private stock offerings, equity raises or strategic partner arrangements resulting in the receipt of at least $65.0 million in aggregate net cash proceeds on or prior to May 31, 2015, it will be permitted to make interest-only payments through December 1, 2015 rather than July 1, 2015, and beginning on January 1, 2016, the Company would be required to make principal and accrued interest payments in equal monthly installments over a term of 30 months.
	The future principal payments under the New Credit Facility are currently as follows (in thousands):
	Years ending December 31,
	2014	$	—
	2015	3,500
	2016	7,000
	2017	7,000
	2018	3,500
		$	21,000
	In addition to the Initial Term Loan, the Company would have been able to request an additional term loan in an aggregate principal amount of $9.0 million (“Second Term Loan”) after the completion of this initial public offering if the net cash proceeds were at least $65.0 million subject to certain customary conditions to funding. Given the net proceeds from the Company’s initial public offering were less than $65.0 million, it was not able to request the Second Term Loan. The Initial Term Loan bears interest per annum at 9.85% plus one-month LIBOR (customarily defined). All principal and accrued interest on the initial term loan is due on June 1, 2018.
	The Company used approximately $9.3 million of the Initial Term Loan to repay all the amounts owed under its existing credit facility with General Electric Capital Corporation and Oxford.
	As security for its obligations under the New Credit Facility, the Company granted a security interest in substantially all of its existing and after-acquired assets except for our intellectual property and certain other customary exclusions.
	On May 30, 2014, pursuant to the Loan and Security Agreement with Solar and Oxford, the Company issued to Solar and Oxford warrants to purchase an aggregate of up to 10,258 shares of its series B-2 convertible preferred stock (“Series B-2”) at an exercise price equal to $61.42 per share. The warrants were initially classified as liabilities in the Company’s balance sheet and were re-measured at their estimated fair value through completion of the Company’s initial public offering. The changes in fair value are recorded as other income (expense) in the statement of operations. Upon the closing of its initial public offering at a price of $8.00 per share and the automatic conversion of the Series B-2 into common stock, these warrants became exercisable for up to 78,760 shares of common stock. Subsequent to the initial public offering, the Company’s warrant liability was reclassified to equity. These warrants are immediately exercisable for cash or by net exercise and will expire five years from their issuance.
	The initial fair value of the warrants issued in connection with Loan and Security agreement was $0.3 million and was recorded as a discount to the Initial Term Loan.  The Company also paid Solar and Oxford a facility fee of $0.3 million and reimbursed certain costs associated with the Loan and Security Agreement of approximately $0.1 million, both of which were also recorded as a discount to the Initial Term Loan. The discount is being amortized to interest expense over the 48 month period that the Initial Term Loan is expected to be outstanding using the effective interest method.

Convertible_Preferred_Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2014
Convertible Preferred Stock	'
Convertible Preferred Stock	'
	5. Convertible Preferred Stock
	Below is a summary of the rights, preferences, and privileges of the Series B convertible preferred stock (“Series B”), Series B-2, Series A-1 convertible preferred stock (“Series A-1”), Series A-2 convertible preferred stock (“Series A-2”), Series A-3 convertible preferred stock (“Series A-3”), Series A-4 convertible preferred stock (“Series A-4”), Series A-5 convertible preferred stock (“Series A-5”) and Series A-6 convertible preferred stock (“Series A-6”) (the Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6, collectively, the “Series A Preferred Stock”) prior to the conversion of all outstanding convertible preferred stock into common stock upon completion of the Company’s initial public offering on June 11, 2014.
	On February 14, 2014, the Company entered into a Series B-2 Convertible Preferred Stock and Warrant Purchase Agreement (the “Series B-2 Purchase Agreement”), pursuant to which the Company was able to raise up to approximately $40.2 million through the issuance of (1) up to 655,000 shares of its Series B-2 and (2) warrants to acquire up to 718,201 shares of its common stock with an exercise price of $14.004 per share. In February and March 2014, the Company consummated closings under the Series B-2 Purchase Agreement, whereby, in exchange for aggregate gross proceeds to the Company of approximately $27.5 million, the Company issued an aggregate of 448,060 shares of Series B-2 and warrants to purchase up to a total of 491,293 shares of its common stock.
	Conversion— Any holder of the Company’s preferred stock had the right, at any time or from time to time, to convert any or all of its shares of preferred stock into fully paid and non-assessable shares of the Company’s common stock for each share of preferred stock converted based upon the then in effect Conversion Price (“Conversion Feature”).  If the Company issued or sold any shares of its Common Stock (as defined by the Company’s certificate of incorporation) or options to purchase or other rights to subscribe for such convertible or exchangeable securities, in each case other than Excluded Stock (as defined by the Company’s certificate of incorporation), for a consideration per share less than the then in effect conversion price (“Dilutive Issuance”) of the Company’s Series A-1, A-2, A-3, B, or B-2 preferred stock, respectively, the Conversion Price for such series in effect immediately prior to each such Dilutive Issuance would automatically be reduced in accordance with the provisions set forth in the Certificate of Designations.  Upon issuance of each series of the Company’s preferred stock, the respective Conversion Prices were greater than the fair value of the Company’s common stock at the respective commitment dates.  Therefore, the Conversion Feature was not considered to be a beneficial conversion feature that would require the Company to record a deemed dividend on the preferred stock.  Each holder of Series B and Series B-2 shares had the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as determined by dividing the original purchase price of $61.42 by the conversion price (“Series B Optional Conversion”). The conversion price of the Series B and Series B-2 as of June 6, 2014 was $14.004 per share and $8.00 per share, respectively, (the “Series B Conversion Price”), which represented a conversion ratio of one share of Series B or Series B-2 into approximately 4.386 and 7.678 shares of common stock, respectively.
	Each holder of Series A-1, Series A-2 and Series A-3 had the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as determined by dividing the original purchase price of $81.42 by the conversion price (“Optional Conversion”). The original conversion price of the Series A-1, Series A-2 and Series A-3 was $18.564 per share (the “Conversion Price”), which represented a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into approximately 4.386 shares of common stock. The issuance of the Series B in April and May of 2013 and the Series B-2 in February and March of 2014 resulted in an adjustment to the Conversion Price of the Series A-1, Series A-2 and Series A-3 (the “Anti-Dilution Adjustment”).  As a result of the Anti-Dilution Adjustment, the conversion price of each share of Series A-1, Series A-2 and Series A-3 was reduced to $16.970, which represented a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into approximately 4.798 shares of common stock.  This reduction of the Conversion Price did not create a beneficial conversion feature that would require the Company to record a deemed dividend on the Series A-1, Series A-2 or Series A-3 preferred stock.
	Each holder of Series A-4, Series A-5 and Series A-6 had the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as determined by dividing the original purchase price of $81.42 by the conversion price. The Conversion Price of the Series A-4, Series A-5 and Series A-6 as of June 6, 2014 was $18.564 per share, which represented a conversion ratio of one share of Series A-4, Series A-5 or Series A-6 into approximately 4.386 shares of common stock.
	Upon an optional conversion, the holders of the converted Series B-2, Series B and Series A Preferred Stock were entitled to payment of all accrued, whether or not declared, but unpaid dividends in shares of the common stock of the Company at the then effective Conversion Price.
	Each share of the Series B, Series B-2 and Series A Preferred Stock was automatically convertible into fully paid and non-assessable shares of common stock at the applicable conversion price (as described above) in effect upon, in the case of the Series A and Series B Preferred Stock, upon (1) a vote of the holders of at least 70% of the outstanding shares of Series B, Series B-2, Series A-1, Series A-2 and Series A-3 to convert all shares of Series B, Series B-2 and Series A Preferred Stock or (2) the common stock becoming listed for trading on a national stock exchange, and in the case of the Series B-2 Preferred Stock, upon (1) a vote of the holders of at least 70% of the outstanding shares of Series B-2 to convert all shares of Series B-2 Preferred Stock, (2) the closing of a firm commitment underwritten public offering on or prior to June 30, 2014 or (3) after June 30, 2014, the common stock becoming listed for trading on a national stock exchange (“Special Mandatory Conversion”). Upon a Special Mandatory Conversion, all accrued, whether or not declared, but unpaid dividends were to be paid in cash or shares of common stock (calculated based on the then effective conversion price) at the discretion of the Company’s Board of Directors.
	In the event of a conversion upon the closing of a firm commitment underwritten public offering on or prior to June 30, 2014 in which the public offering price per share is less than the Series B-2 Conversion Price, then the Series B-2 Conversion Price was automatically reduced to the price equal to the public offering price.
	Redemption— Unless redemption was waived by a requisite stockholder vote or consent, the shares of Series B, Series B-2 and Series A Preferred Stock were automatically redeemable upon an event of sale of the Company.  The shares of Series B, Series B-2 and Series A Preferred Stock were not redeemable at the option of the holder.
	Dividends— Holders of shares of Series B and Series B-2 were entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrued on a daily basis commencing on the date of issuance of the shares of Series B and Series B-2. Dividends were payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series B and Series B-2 were also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B and Series B-2, holders of shares of Series A-1 were entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrued on a daily basis commencing on the date of issuance of the shares of Series A-1. Dividends were payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-1 were also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, Series B-2 and Series A-1, holders of Series A-2 were entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrued on a daily basis commencing on the date of issuance of the shares of Series A-2. Dividends were payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-2 were also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, Series B-2, Series A-1 and Series A-2, holders of Series A-3 were entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrued on a daily basis commencing on the date of issuance of the shares of Series A-3. Dividends were payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-3 were also entitled to dividends declared or paid on any shares of common stock.
	Without regard to the payment of required dividends to the holders of Series B, Series B-2, Series A-1, Series A-2 and Series A-3, holders of Series A-5 were entitled to receive the Series A-5 Special Accruing Dividend (as defined in the Company’s certificate of incorporation) paid in shares of Series A-6 as described in note 7. Dividends were payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-5 were also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, Series B-2, Series A-1, Series A-2, Series A-3 and Series A-5, holders of Series A-4 and Series A-6 were entitled to receive, when, if and as declared by the Board of Directors, dividends on any shares of Series A-4 Stock or Series A-6 Stock, as the case may be, out of funds legally available for that purpose, at a rate to be determined by the Board of Directors if and when they may so declare any dividend on the Series A-4 Stock or A-6 Stock, as the case may be. Dividends were payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-4 and Series A-6 were also entitled to dividends declared or paid on any shares of common stock.
	As of June 6, 2014, the Company had accrued dividends of $3.9 million, $18.1 million, $21.2 million and $3.1 million on Series B, Series A-1, Series A-2 and Series A-3, respectively. As of June 11, 2014 the Company had accrued dividends of $0.7 million on Series B-2. Upon completion of the Company’s initial public offering, all accrued dividends were paid in shares of common stock at the then effective Conversion Price.
	Voting—The holders of Series B, Series B-2 and Series A Preferred Stock were entitled to vote together with the holders of the common stock as one class on an as-if converted basis.  In addition, as long as the shares of Series A-1 were outstanding, the holders of Series A-1, voting as a separate class, had the right to elect two members of the Company’s Board of Directors.
	Liquidation— The shares of Series B and Series B-2 ranked equally to other shares of Series B and Series B-2, and ranked senior to the Series A-1 and all other classes of Series A Preferred Stock.  The shares of Series A-1 ranked senior to all other classes of Series A Preferred Stock. Series A-2 ranked junior to Series A-1 and senior to Series A-3, Series A-4, Series A-5 and Series A-6. Series A-3, Series A-5 and Series A-6 ranked equally but junior to Series A-1 and Series A-2 and senior to Series A-4. Series A-4 ranked senior to the Company’s common stock.
	In the event of a liquidation, dissolution, or winding-up of the Company, the holders of Series B and Series B-2 were entitled to be paid first out of the assets available for distribution, before any payment is made to the Series A Preferred Stock. Payment to the holders of Series B was to consist of two (2) times the original purchase price of $61.42, plus all accrued but unpaid dividends. Payment to the holders of Series B-2 was to consist of one and a half (1.5) times the original purchase price of $61.42, plus all accrued but unpaid dividends. After such distribution to the holders of Series B and Series B-2, the holders of Series A-1 would have been entitled to be paid out of the remaining assets available for distribution, before any payment is made to the Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6. Payment to the holders of Series A-1 was to consist of the original purchase price of $81.42, plus all accrued but unpaid dividends. After the distribution to the holders of Series A-1, the holders of Series A-2 would have been entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid dividends. After the distribution to the holders Series A-1 and Series A-2, the holders of Series A-3, Series A-5 and Series A-6, would have been entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid or declared and unpaid dividends, as appropriate. After the distribution to the holders Series A-1, Series A-2, Series A-3, Series A-5 and Series A-6, the holders of Series A-4 would have been entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any declared and unpaid dividends.  If the assets of the Company were insufficient to pay the full preferential amounts to the holders of Series B, the assets would have been distributed ratably among the holders of Series B in proportion to their aggregate liquidation preference amounts.  If the assets of the Company were insufficient to pay the full preferential amounts to the holders of Series A-1, the assets would have been distributed ratably among the holders of Series A-1 in proportion to their aggregate liquidation preference amounts. If the assets of the Company were insufficient to pay the full preferential amounts to the holders of Series A-2, the assets would have been distributed ratably among the holders of Series A-2 in proportion to their aggregate liquidation preference amounts. If the assets of the Company were insufficient to pay the full preferential amounts to the holders of Series A-3, Series A-5 and Series A-6, the assets would have been distributed ratably among the holders of Series A-3, Series A-5 and Series A-6 in proportion to their aggregate liquidation preference amounts. If the assets of the Company were insufficient to pay the full preferential amounts to the holders of Series A-4, the assets would have been distributed ratably among the holders of Series A-4 in proportion to their aggregate liquidation preference amounts. After all liquidation preference payments have been made to the holders of the Series B, Series B-2 and Series A Preferred Stock, the holders of the Series B, Series B-2 and Series A-1, Series A-2 and Series A-3 were to participate in the distribution of the remaining assets with the holders of the Company’s common stock on an as-if converted basis.
	In the event of, and simultaneously with, the closing of an event of sale of the Company (as defined in the Company’s Amended Certificate of Incorporation), the Company was to redeem all of the shares of Series B, Series B-2 and Series A Preferred Stock then outstanding at the Special Liquidation Price, as defined. If the event of sale involved consideration other than cash, the Special Liquidation Price could have been paid with such consideration having a value equal to the Special Liquidation Price. The Special Liquidation Price was to be equal to an amount per share, which would be received by each holder of the Preferred Stock if, in connection with the event of sale, all the consideration paid in exchange for the assets or the shares of capital stock of the Company was actually paid to and received by the Company, and the Company was immediately liquidated thereafter and its assets distributed pursuant to the liquidation terms above.

Marketable_Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2014
Marketable Securities	'
Marketable Securities	'
	6. Marketable Securities
	Available-for-sale marketable securities and cash and cash equivalents consist of the following (in thousands):
		June 30, 2014
		Amortized Cost		Gross Unrealized		Gross Unrealized			Fair Value
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	1,133	$	—	$	—		$	1,133
	Money market funds	31,417		—		—			31,417
	Domestic corporate debt securities	5,382		—		(1		)	5,381
	Domestic corporate commercial paper	10,439		1		—			10,440
	Total	$	48,371	$	1	$	(1	)	$	48,371
	Marketable securities:
	Domestic corporate debt securities	22,157		—		(5		)	22,152
	Domestic corporate commercial paper	8,492		6		—			8,498
	Total	$	30,649	$	6	$	(5	)	$	30,650
		December 31, 2013
		Amortized Cost		Gross Unrealized		Gross Unrealized			Fair Value
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	2,710	$	—	$	—		$	2,710
	Money market fund	9,593		—		—			9,593
	Total	$	12,303	$	—	$	—		$	12,303
	There were no debt securities that had been in an unrealized loss position for more than 12 months as of June 30, 2014 or December 31, 2013. There were 13 debt securities in an unrealized loss position for less than 12 months at June 30, 2014 and there were no debt securities that had been in an unrealized loss position for less than 12 months at December 31, 2013. The aggregate unrealized loss on these securities as of June 30, 2014 was less than $5.0 thousand and the fair value was $27.5 million. The Company considered the decline in market value for these securities to be primarily attributable to current economic conditions. As it was not more likely than not that the Company would be required to sell these securities before the recovery of their amortized cost basis, which may be maturity, the Company did not consider these investments to be other-than-temporarily impaired as of June 30, 2014.
	The contractual term to maturity of all marketable securities held by the Company as of June 30, 2014 is less than one year.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	7. Fair Value Measurements
	The Company determines the fair values of its financial instruments based upon the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Below are the three levels of inputs that may be used to measure fair value:
	·    Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	·    Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	·    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	1,133		$	—	$	—	$	1,133
	Money market funds (1)	31,417			—		—		31,417
	Domestic corporate debt securities (2)	—			5,381		—		5,381
	Domestic corporate commercial paper (2)	—			10,440		—		10,440
	Total	$	32,550		$	15,821	$	—	$	48,371
	Marketable securities:
	Domestic corporate debt securities (2)	—			22,152		—		22,152
	Domestic corporate commercial paper (2)	—			8,498		—		8,498
	Total	$	—		$	30,650	$	—	$	30,650
		December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	2,710		$	—	$	—	$	2,710
	Money market funds (1)	9,593			—		—		9,593
		$	12,303		$	—	$	—	$	12,303
	Liabilities
	Warrant liability (3)	$	—		$	—	$	1,945	$	1,945
	Stock liability (3)	—			—		5,328		5,328
		$	—		$	—	$	7,273	$	7,273
	(1)              Fair value is based upon quoted market prices.
	(2)              Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.  Inputs are obtained from various sources, including market participants, dealers and brokers.
	(3)              Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below.  Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.
	The stock asset represents the prepaid balance and the stock liability represents the accrued balance of the research and development expense related to the stock dividends that were issuable to Nordic Bioscience Clinical Development VII A/S (“Nordic”) in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) as of December 31, 2013, for services rendered which is being recognized ratably over the estimated per patient treatment period under the three work statements executed with Nordic (the “Nordic Work Statements”) (see note 9). The fair value of the stock asset and stock liability was based upon the fair value of the Series A-6 as determined using PWERM, which considered the value of the Company’s various classes of preferred stock. The fair value of the Company’s various classes of preferred stock was determined through an analysis of the future values for equity assuming various future outcomes. Accordingly, share value was based upon the probability weighted present value of expected future net cash flows, considering each of the possible future events, discount rate as determined using the capital asset pricing model, as well as the rights and preferences of each share class. PWERM is complex as it requires numerous assumptions relating to potential future outcomes of equity. Accordingly, the valuation of the Company’s stock asset and stock liability was determined using Level 3 inputs. Upon completion of the Company’s initial public offering, any payments owed by the Company to Nordic in relation to the Nordic Work Statements were changed from the right to receive shares of Series A-6 to the right to receive a total cash payment from the Company of $4.3 million.
	The warrant liability represents the liability for the warrants issued to the placement agent in connection with the Company’s Series A-1 financing, to the investors in the Series B financing in April and May 2013 and the Series B-2 financing in February and March 2014, and to the lenders in connection with the Company’s Loan and Security Agreement executed with Oxford and General Electric Capital Corporation in May 2011 and the Company’s Loan and Security Agreement with Solar and Oxford. The warrant liability is calculated using the Black-Scholes option pricing method. This method of valuation includes using inputs such as the fair value of the Company’s common stock or preferred stock, historical volatility, the term of the warrant and risk free interest rates. Prior to its initial public offering, the fair value of the Company’s shares of common stock and preferred stock is estimated using PWERM, as described above. Accordingly, the valuation of the warrant liability at December 31, 2013, was determined using Level 3 inputs. Upon completion of the Company’s initial public offering, the outstanding warrants to purchase shares of A-1 convertible preferred stock and warrants to purchase shares of series B-2 convertible preferred stock were converted into the right to purchase shares of common stock and the Company’s warrant liability was reclassified to equity.
	The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2013	$	—
	Issuance of shares of Series A-6 - prepayment	1,220
	Nordic amendment	(1,220		)
	Balance at June 30, 2014	$	—
	The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2013	$	7,273
	Issuance of shares of Series A-6	(8,889		)
	Additions — accrued shares of Series A-6	2,717
	Additions — warrants	1,511
	Change in fair value	505
	Warrant liability reclassified to equity	(3,117		)
	Balance at June 30, 2014	$	—
	Additions represent the value of the asset or liability for additional accrued shares of stock that were issuable to Nordic for services rendered in connection with the Company’s Phase 3 Clinical Trial of Abaloparatide-SC (see note 9), as well as the value of any new warrants issued during the period. The issuance of shares of Series A-6 represents the release of the quarterly stock dividends of Series A-6 accrued under the Nordic Work Statements as of June 30, 2014 (see note 9). The Nordic amendment represents amounts that were originally payable in shares of Series A-6, but converted to the right to receive cash upon completion of the Company’s initial public offering and no longer require fair value measurement at June 30, 2014 (see note 9).
	The fair value of the Company’s note payable is determined using current applicable rates for similar instruments as of the balance sheet date. The carrying value of the Company’s note payable approximated its fair value as of June 30, 2014, as the Company’s interest rate is near current market rates. The fair value of the Company’s notes payable was determined using Level 3 inputs.

License_Agreements

License Agreements	6 Months Ended
	Jun. 30, 2014
License Agreements	'
License Agreements	'
	8. License Agreements
	On September 27, 2005, the Company entered into a license agreement (the “Ipsen Agreement”), as amended, with SCRAS S.A.S, a French corporation on behalf of itself and its affiliates (collectively, “Ipsen”). Under the Ipsen Agreement, Ipsen granted to the Company an exclusive right and license under certain Ipsen compound technology and related patents to research, develop, manufacture and commercialize certain compounds and related products in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. With respect to France, if Ipsen exercises its co-marketing and co-promotion rights, then Ipsen may elect to receive a percentage of the aggregate revenue from the sale of products by both parties in France (subject to a mid-double digit percentage cap) and Ipsen shall bear a corresponding percentage of the costs and expenses incurred by both parties with respect to such marketing and promotion efforts in France; Ipsen shall also pay Radius a mid-single digit royalty on Ipsen’s allocable portion of aggregate revenue from the sale of products by both parties in France. Abaloparatide (the Company’s bone growth drug) is subject to the Ipsen Agreement. Ipsen also granted the Company an exclusive right and license under the Ipsen compound technology and related patents to make and have made compounds or product in Japan. Ipsen also granted the Company an exclusive right and license under certain Ipsen formulation technology and related patents solely for purposes of enabling the Company to develop, manufacture and commercialize compounds and products covered by the compound technology license in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. In consideration for these licenses, the Company made a nonrefundable, non-creditable payment of $250,000 to Ipsen, which was expensed during 2005. The Ipsen Agreement provides for further payments in the range of €10.0 million to €36.0 million ($13.7 million to $49.3 million) to Ipsen upon the achievement of certain development and commercialization milestones specified in the Ipsen Agreement, and for the payment of fixed 5% royalties on net sales of any product by the Company or its sub-licensees on a country-by-country basis until the last to expire of the licensed patents or for a period of 10 years after the first commercial sale in such country of any product that includes the compound licensed from Ipsen or any analog thereof, whichever is longer.
	If the Company sublicenses the rights licensed from Ipsen, then the Company will also be required to pay Ipsen a percentage of certain payments received from such sublicensee (in lieu of milestone payments not achieved at the time of such sublicense). The applicable percentage is in the low double digit range. In addition, if the Company or its sub-licensees commercialize a product that includes a compound discovered by it based on or derived from confidential Ipsen know-how, it will be obligated to pay to Ipsen a fixed low single digit royalty on net sales of such product on a country-by-country basis until the last to expire of its patents that cover such product or for a period of 10 years after the first commercial sale of such product in such country, whichever is longer. In connection with the Ipsen Agreement, the Company recorded $0.2 million and $0.1 million in costs during the three months ended June 30, 2014 and 2013, respectively, and $0.2 million and $0.1 million during the six months ended June 30, 2014 and 2013, respectively, which were incurred by Ipsen and charged to the Company for the manufacture of the clinical supply of the licensed compound.

Research_Agreements

Research Agreements	6 Months Ended
	Jun. 30, 2014
Research Agreements	'
Research Agreements	'
	9. Research Agreements
	Abaloparatide-SC Phase 3 Clinical Trial—On March 29, 2011, the Company and Nordic entered into a Clinical Trial Services Agreement, a Work Statement NB-1 (the “Work Statement NB-1”) under such Clinical Trial Services Agreement and a related Stock Issuance Agreement, as amended to date (the “Stock Issuance Agreement”). Pursuant to the Work Statement NB-1, Nordic is managing the Phase 3 Clinical Trial (the “Phase 3 Clinical Trial”) of Abaloparatide-SC and is being compensated for such services in a combination of cash and shares of stock.
	In December 2011, the Company entered into an amendment to the Work Statement NB-1(the “First Amendment”). Pursuant to the original terms of the Work Statement NB-1, the study was to be conducted in 10 countries at a specified number of sites within each country. The terms of the First Amendment (1) provided for two additional countries (the United States and India) in which the trial would be conducted, (2) specified a certain number of sites within each such additional country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect the addition of such countries and sites within the study’s parameters. Payments to be made by the Company to Nordic under the First Amendment are denominated in both euros and U.S. dollars and total up to €717,700 ($982,531) and $289,663, respectively, for the 15 additional study sites in India contemplated by the First Amendment and up to €1.2 million ($1.6 million) and $143,369, respectively, for the five additional study sites in the United States contemplated by the First Amendment.
	In June 2012, the Company entered into a second amendment to the Work Statement NB-1(the “Second Amendment”). Pursuant to the original terms of the Work Statement NB-1, as amended by the First Amendment, the study was to be conducted in 12 countries at a specified number of sites within each country. The terms of the Second Amendment (1) increased the overall number of sites by adding sites in Europe, Brazil and Argentina and removing other sites, (2) specified a certain number of sites within each country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect additional services to be provided at existing sites and the addition of the new study sites within the study’s parameters. The Second Amendment also provided that cash payments to Nordic under the Clinical Trial Services Agreement as well as the payment of shares of stock under the related Stock Issuance Agreement will each be reduced by an amount of €11,941 ($16,347) per subject for any subjects enrolled in India or the United States. Such reductions are applied in pro rata monthly installments. Payments to be made by the Company to Nordic under the Second Amendment in connection with the additional services provided at existing sites and the conduct of the study at the new study sites are denominated in both euros and U.S. dollars and total of up to €3.7 million ($5.1 million) and $205,540, respectively.
	In March 2014, the Company entered into a fourth amendment to the Work Statement NB-1 (the “Fourth Amendment”).  Pursuant to the terms of the Fourth Amendment, the Company agreed to pay to Nordic an additional performance incentive, or a Performance Incentive Payment, of $500,000 for every 50 patients that, subsequent to March 28, 2014, complete all end-of-study procedures, up to a maximum aggregate amount of additional payments equal to $5.0 million. Any Performance Incentive Payment would have been paid in cash in the event that the Company’s initial public offering of its common stock was completed prior to May 31, 2014. If an initial public offering was not completed prior to May 31, 2014, any Performance Incentive Payments would have been paid through the issuance to Nordic of shares of capital stock of the Company under the same model for equity-based compensation contemplated by the Company’s existing outstanding work statements under the Clinical Trial Services Agreement. On May 19, 2014, the Company entered into a fifth amendment to Work Statement NB-1, which amended the date prior to which an initial public offering must be completed to June 30, 2014. As the Company completed an initial public offering of its common stock on June 11, 2014, all Performance Incentive Payments will be paid in cash.
	Pursuant to the Work Statement NB-1, the Company is required to make certain per patient payments denominated in both euros and U.S. dollars for each patient enrolled in the Phase 3 Clinical Trial followed by monthly payments for the duration of the study and final payments in two equal euro-denominated installments and two equal U.S. dollar-denominated installments. Changes to the Clinical Trial schedule may alter the timing, but not the aggregate amounts of the payments.
	The Work Statement NB-1, as amended on December 9, 2011, June 18, 2012, March 28, 2014 and May 19, 2014, provides for a total of up to approximately €41.2 million ($56.3 million) of euro-denominated payments and a total of up to approximately $3.2 million of U.S. dollar-denominated payments over the course of the Phase 3 Clinical Trial, plus Performance Incentive Payments of up to $5.0 million. These payments may be adjusted based upon actual sites opened, work performed or number of patients enrolled.
	Pursuant to the Stock Issuance Agreement, Nordic agreed to purchase the equivalent of €371,864 of Series A-5 at $8.142 per share, and 64,430 shares of Series A-5 were sold to Nordic on May 17, 2011 for proceeds of $525,154. These shares were exchanged in the Merger for an aggregate of 6,443 shares of the Company’s Series A-5.
	The Stock Issuance Agreement provided that Nordic was entitled to receive quarterly stock dividends, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock had been converted in accordance with its amended certificate of incorporation, having an aggregate value, under the Work Statement NB-1, of up to €36.8 million ($50.4 million) (the “Nordic Accruing Dividend”). In the event Nordic sold the shares of Series A-5 or in the event the shares of Series A-5 were converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend would terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, would remain with Nordic as a contractual right under the Stock Issuance Agreement.
	On March 28, 2014, the Company entered into Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011 (the “Second Stock Issuance Agreement Amendment”), with Nordic.  The Second Stock Issuance Agreement Amendment required that the Company’s Board of Directors declare, as soon as reasonably practical, a stock dividend of twenty nine (29) shares of its Series A-6 for each share of the Company’s then outstanding Series A-5, all of which were held by Nordic, for a total of 186,847 shares of Series A-6, in full satisfaction of all stock dividends payable in 2014 under the terms of the Stock Issuance Agreement in relation to Work Statement NB-1 and Work Statement NB-3. In March 2014, Nordic requested that all 186,847 shares of Series A-6 be issued.  Accordingly, the Company’s Board of Directors declared and issued a dividend to Nordic of all 186,847 shares on March 31, 2014.  The Second Stock Issuance Agreement Amendment further provided that in the event an initial public offering of the Company’s common stock occurred prior to May 31, 2014, any payments owed by the Company to Nordic in relation to Work Statement NB-1 and Work Statement NB-3, excluding Performance Incentive Payments, for all periods of time after 2014, would be changed from the right to receive stock to the right to receive a total cash payment from the Company of $4.3 million payable in ten equal monthly installments of $430,000 beginning on March 31, 2015. On May 19, 2014, the Company entered into Amendment No. 3 to the Stock Issuance Agreement, which amended the date prior to which an initial public offering must occur to June 30, 2014.  The Second Stock Issuance Agreement Amendment also stipulated that all consideration to be paid to Nordic pursuant to the Stock Issuance Agreement at any time after the consummation of an initial public offering be payable in cash. As the Company completed an initial public offering on June 11, 2014, Nordic no longer has the right to receive stock from the Company and agreed to be paid in cash for all periods after the consummation of the initial public offering.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company’s balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares were recorded as a gain or loss in other (expense) income in the statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-1, First Amendment and Second Amendment ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 3 Clinical Trial, or a twenty-month period. The Company recognizes research and development expense for the amounts due to Nordic under the Fourth Amendment on a per patient basis when the End-of-Study visit and all other required procedures are completed. The Company recorded $2.4 million and $8.8 million of research and development expense during the three months ended June 30, 2014 and 2013, respectively and $6.9 million and $17.9 million during the six months ended June 30, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Phase 3 Clinical Study.
	As of June 30, 2014, the Company had a liability of $11.4 million reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.
	Abaloparatide-SC Phase 3 Clinical Extension Study—In February 2013, the Company entered into a Work Statement NB-3 (the “Work Statement NB-3”) under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to Work Statement NB-3, Nordic will perform an extension study to evaluate six months of standard-of-care osteoporosis management following the completion of the 18-month Abaloparatide-SC Phase 3 Clinical Trial (the “Extension Study”) and will be compensated for such services in a combination of cash and shares of stock. Under the terms of a Letter of Intent that the Company entered into with Nordic on October 22, 2012 setting forth the parties’ obligations to negotiate in good faith to enter into Work Statement NB-3, the Company was required to make an initial payment of €806,468 ($1.1 million).
	In March 2014, the Company entered into an amendment to the Work Statement NB-3 (the “NB-3 Amendment”).  The NB-3 Amendment was effective as of February 28, 2014 and provides that Nordic will perform a Period 2 extension study (the “Second Extension”), to evaluate an additional eighteen months of standard-of-care osteoporosis management following the Period 1 extension of six months upon completion of the Phase 3 clinical trial of the Company’s Abaloparatide-SC product.  Payments in cash to be made by the Company to Nordic under the NB-3 Amendment are denominated in both euros and U.S. dollars and total up to approximately €3.0 million ($4.1 million) and $527,740, respectively.  In addition, the Company agreed to issue to Nordic shares of the Company’s series A-6 having a value of up to approximately €3.0 million ($4.1 million) and $527,740 as additional payment for the services to be provided under the NB-3 Amendment, with the issuance of such shares to be made pursuant to the terms of an Amendment No. 2, entered into by the Company with Nordic on March 28, 2014, to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.
	Payments in cash to be made to Nordic under the Work Statement NB-3, as amended by the NB-3 Amendment, are denominated in both euros and U.S. dollars and total up to €7.5 million ($10.3 million) and $1.1 million, respectively. In addition, the Company will issue to Nordic, shares of the Company’s Series A-6 having a value of up to €7.5 million ($10.3 million) and $0.8 million, as additional payment for services to be provided under the Work Statement NB-3 and the Services Agreement.
	The Stock Issuance Agreement provided that, beginning with the quarter ended March 31, 2013, Nordic was entitled to receive quarterly stock dividends in connection with services performed under the Work Statement NB-3, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock automatically converted into common stock in accordance with its amended certificate of incorporation, having an aggregate value of up to €7.5 million ($10.3 million) and $0.8 million. In the event Nordic sold the shares of Series A-5 or in the event the shares of Series A-5 were converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend would terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, would remain with Nordic as a contractual right under the Stock Issuance Agreement.
	On March 28, 2014, the Company entered into Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011 (the “Second Stock Issuance Agreement Amendment”), with Nordic.  The Second Stock Issuance Agreement Amendment required that the Company’s Board of Directors declare, as soon as reasonably practical, a stock dividend of twenty nine (29) shares of its Series A-6 for each share of the Company’s then outstanding Series A-5, all of which were held by Nordic, for a total of 186,847 shares of Series A-6, in full satisfaction of all stock dividends payable in 2014 under the terms of the Stock Issuance Agreement in relation to Work Statement NB-1 and Work Statement NB-3. In March 2014, Nordic requested that all 186,847 shares of Series A-6 be issued.  Accordingly, the Company’s Board of Directors declared and issued a dividend to Nordic of all 186,847 shares on March 31, 2014.  The Second Stock Issuance Agreement Amendment further provided that in the event an initial public offering of the Company’s common stock occurred prior to May 31, 2014, any payments owed by the Company to Nordic in relation to Work Statement NB-1 and Work Statement NB-3, excluding Performance Incentive Payments, for all periods of time after 2014, would be changed from the right to receive stock to the right to receive a total cash payment from the Company of $4.3 million payable in ten equal monthly installments of $430,000 beginning on March 31, 2015. On May 19, 2014, the Company entered into Amendment No. 3 to the Stock Issuance Agreement, which amended the date prior to which an initial public offering must occur to June 30, 2014.  The Second Stock Issuance Agreement Amendment also stipulated that all consideration to be paid to Nordic pursuant to the Stock Issuance Agreement at any time after the consummation of an initial public offering be payable in cash. As the Company completed an initial public offering on June 11, 2014, Nordic no longer has the right to receive stock from the Company and agreed to be paid in cash for all periods after the consummation of the initial public offering.
	Prior to the issuance of the shares of Series A-6 to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company’s balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other (expense) income in the statement of operations.
	On December 6, 2013, the Company entered into a Letter of Intent (the “Letter of Intent”) with Nordic, which provided that the Company and Nordic would continue to negotiate the definitive terms of the NB-3 Amendment, which provides for an additional 18 months of standard-of-care treatment for those patients enrolled in the Extension Study being performed under Work Statement NB-3. The NB-3 Amendment was executed on March 28, 2014 and provides for payment by the Company to Nordic of both cash and equity compensation in consideration of the services provided by Nordic, with the equity portion of such compensation to be made pursuant to an Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011. Pursuant to the Letter of Intent, the Company was required to make an initial payment of €222,573 ($0.3 million) and agreed to commence payment of the cash compensation due in consideration of the services being provided by Nordic under the Amendment.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-3 and Amendment ratably over the estimated per patient treatment periods beginning upon enrollment, or over a nine-month and nineteen-month period, respectively. The Company recorded $2.9 million and $0.8 million of research and development expense during the three months ended June 30, 2014 and 2013, respectively, and $5.4 million and $1.3 million for the six months ended June 30, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Extension Study and Second Extension.
	As of June 30, 2014, the Company had a liability of $2.7 million reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.
	Abaloparatide-TD Phase 2 Clinical Trial—On July 26, 2012, the Company entered into a Letter of Intent (the “Phase 2 Letter of Intent”) with Nordic, which provided that the Company and Nordic would, subject to compliance by the Company with certain requirements of its Certificate of Incorporation and applicable securities laws, negotiate in good faith to enter into (1) a Work Statement NB-2 (the “Work Statement NB-2”), a draft of which is attached to the Phase 2 Letter of Intent, and (2) an amendment to the Amended and Restated Stock Issuance Agreement.
	In February 2013, the Company executed the final Work Statement NB-2 under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to the Work Statement NB-2, Nordic would provide clinical trial services relating to the Phase 2 Clinical Trial and would be compensated for such services in a combination of cash and shares of stock. Payments in cash to be made by the Company to Nordic under the Work Statement NB-2 were denominated in both euros and U.S. dollars and totaled up to €3.6 million ($4.9 million) and $0.3 million, respectively. In addition, the Company would issue to Nordic shares of its Series A-6 stock having a value of up to $2.9 million, as additional payment for services to be provided under the Work Statement NB-2 and the Clinical Trial Services Agreement.
	As of December 31, 2013, 32,215 shares of Series A-6 were due to Nordic under Work Statement NB-2, or, after the automatic conversion into common stock of the Company’s preferred stock, 141,294 shares the Company’s common stock. In December 2013, Nordic requested that all 32,215 shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-2 be issued. Accordingly, the Company’s Board of Directors declared a dividend to Nordic of all 32,215 shares of Series A-6 accrued under Work Statement NB-2 on December 31, 2013, which constituted all shares of Series A-6 due under Work Statement NB-2.
	The Company recognized research and development expense for the amounts due to Nordic under the Work Statement NB-2 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 2 Clinical Trial, or a nine-month period. The Company recorded no expense and $1.7 million of research and development expense during the three months ended June 30, 2014 and 2013, respectively, and nil and $3.4 million during the six months ended June 30, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Phase 2 Clinical Trial. As of June 30, 2014, all obligations due to Nordic under Work Statement NB-2 had been paid.
	The Company is also responsible for certain pass-through costs in connection with the Phase 3 Clinical Trial, Extension Study and Phase 2 Clinical Trial. Pass through costs are expensed as incurred or upon delivery. The Company recognized research and development expense of $0.2 million and $0.9 million for pass-through costs during the three months ended June 30, 2014 and 2013, respectively, and $0.5 million and $2.0 million during the six months ended June 30, 2014 and 2013, respectively.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	10. Stock-Based Compensation
	A summary of stock option activity during the six months ended June 30, 2014 is as follows (in thousands, except for per share amounts):
				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2013	1,667		$	7.05
	Granted	1,799		7.9
	Exercised	—		—
	Forfeited	(586	)	8.65
	Expired	(1	)	3.42
	Options outstanding at June 30, 2014	2,879		$	7.26	8.28	$	64,451
	Options exercisable at June 30, 2014	1,363		$	6.51	6.76	$	31,520
	Options vested or expected to vest at June 30, 2014	2,795		$	7.24	8.24	$	62,607
	The weighted-average grant-date fair value per share of options granted during the three and six months ended June 30, 2014 was $4.60 and $4.61, respectively, and the total grant-date fair value of stock options that vested during the six months ended June 30, 2014 was approximately $1.4 million.  As of June 30, 2014, there was approximately $6.5 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately three years.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
Net Loss Per Share	'
	11. Net Loss Per Share
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Numerator:
	Net loss	$	(12,609	)	$	(19,512	)	$	(27,097	)	$	(27,817	)
	Accretion of Preferred Stock	(4,031		)	(4,368		)	(9,000		)	(7,950		)
	Loss attributable to common stockholders - basic and diluted	$	(16,640	)	$	(23,880	)	$	(36,097	)	$	(35,767	)
	Denominator:
	Weighted-average number of common shares used in loss per share - basic and diluted (1)	7,500,148			381,525			3,962,559			380,942
	Loss per share - basic and diluted	$	(2.22	)	$	(62.59	)	$	(9.11	)	$	(93.89	)
	(1)              Common shares adjusted for 2.28:1 stock split that was affected April 24, 2014.
	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three and six months ended June 30, 2014 and 2013, all of the Company’s classes of preferred stock, options to purchase common stock and warrants outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position.
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Convertible preferred stock	7,043,931		7,041,888		7,779,266		6,452,734
	Options to purchase common stock	2,621,820		1,706,787		2,373,083		1,708,460
	Warrants	1,311,356		589,328		1,161,639		303,751

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	12. Commitments and Contingencies
	The Company may be exposed, individually or in the aggregate, to certain claims or assessments in the ordinary course of business. In the opinion of management, the outcome of these matters is not likely to have any material effect on the financial position, results of operations, or cash flows of the Company.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
Subsequent Events	'
	13. Subsequent Events
	Amendment to New Credit Facility—On July 10, 2014, the Company entered into a first amendment to the New Credit Facility (“First Amendment”).  Pursuant to the terms of the New Credit Facility, as amended by the First Amendment, the Company was provided with term loans in an aggregate principal amount of $30.0 million, of which $21.0 million was drawn on May 30, 2014 and $4.0 million was drawn on July 10, 2014.  The Lenders were to fund the remaining term loans in an aggregate principal amount of $9.0 million (the “Original Term B Loans”) at the Company’s request, subject to certain conditions, including the Company completing an initial public offering resulting in $65.0 million in net cash proceeds no later than December 5, 2014. The terms of the First Amendment, among other things,
	·         provide the Company with, subject to certain customary funding conditions, additional term loans in an aggregate principal amount of $4.0 million upon the closing of the First Amendment (the “Modified Term B Loans”).  All other terms applicable to the Original Term B Loans remain applicable to the Modified Term B Loans. The Original Term B Loans are replaced by the Modified Term B Loans.  The Company borrowed the full amount of the Modified Term B Loans on July 10, 2014.
	·         provide the Company the ability to borrow additional term loans in an aggregate amount of $5.0 million (the “Term C Loans”) at any time through December 31, 2014.  In order to draw the Term C Loans, the Company must, in addition to other customary conditions, either (a) close public or private stock offerings, equity raises or strategic partner arrangements resulting in $13.0 million in aggregate net proceeds after the closing of the First Amendment, or (b) as it relates specifically to RAD1901, complete both the maximum tolerable dose trial and enroll the first patient in the breast cancer brain metastasis trial.
	·         required the Company to issue warrants (“New Tranche B Warrants”) for the purchase of 4,706 shares of the Company’s common stock to Solar and 4,706 shares of common stock to Oxford, each at a price per share equal to $12.75. The Company issued the New Tranche B Warrants on July 10, 2014.
	·         if the Term C Loans are funded, the Company will issue to the Lenders warrants to purchase common stock in amounts and subject to terms as were applicable to warrants that would have been issued in connection with the Original Term B Loans.
	Nordic Amendment—On July 22, 2014, the Company entered into a sixth amendment to the Work Statement NB-1(the “Sixth Amendment”). The terms of the Sixth Amendment provide for additional fees to be paid for the initiation of additional clinical sites not contemplated in prior amendments, as well as an increase in planned analytical services.  Payments to be made by the Company to Nordic under the Sixth Amendment are denominated in euros and total up to €833,957 ($1.1 million).

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Basis of Presentation and Significant Accounting Policies	'
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards—In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 were effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company adopted ASU 2013-11 on January 1, 2014.  Its adoption did not have a material impact on the Company’s results of operations, financial position, or cash flows.
	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity (“ASU 2013-12”). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. The Company adopted ASU 2013-12 on January 1, 2014.  Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Expenses and Other Current Liabilities	'
Schedule of accrued expenses and other current liabilities	'
	Accrued expenses and other current liabilities consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
	Research costs - Nordic (1)	$	14,083	$	17,998
	Research costs - other	2,327		1,599
	Payroll and employee benefits	932		1,005
	Professional fees	2,208		426
	Vacation	119		69
	Interest on notes payable	205		852
	Other	21		58
	Total accrued expenses and other current liabilities	$	19,895	$	22,007
	(1)     Includes amounts accrued ratably over the estimated per patient treatment period under the Nordic Work Statement NB-1 and Work Statement NB-3.  Amounts do not include pass-through costs which are expensed as incurred or upon delivery.  See note 9 for additional information.

Loan_and_Security_Agreement_Ta

Loan and Security Agreement (Tables)	6 Months Ended
	Jun. 30, 2014
Loan and Security Agreement	'
Schedule of future principal payments under the New Credit Facility	'
	The future principal payments under the New Credit Facility are currently as follows (in thousands):
	Years ending December 31,
	2014	$	—
	2015	3,500
	2016	7,000
	2017	7,000
	2018	3,500
		$	21,000

Marketable_Securities_Tables

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2014
Marketable Securities	'
Schedule of available-for-sale marketable securities and cash and cash equivalents	'
	Available-for-sale marketable securities and cash and cash equivalents consist of the following (in thousands):
		June 30, 2014
		Amortized Cost		Gross Unrealized		Gross Unrealized			Fair Value
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	1,133	$	—	$	—		$	1,133
	Money market funds	31,417		—		—			31,417
	Domestic corporate debt securities	5,382		—		(1		)	5,381
	Domestic corporate commercial paper	10,439		1		—			10,440
	Total	$	48,371	$	1	$	(1	)	$	48,371
	Marketable securities:
	Domestic corporate debt securities	22,157		—		(5		)	22,152
	Domestic corporate commercial paper	8,492		6		—			8,498
	Total	$	30,649	$	6	$	(5	)	$	30,650
		December 31, 2013
		Amortized Cost		Gross Unrealized		Gross Unrealized			Fair Value
		Value		Gains		Losses
	Cash and cash equivalents:
	Cash	$	2,710	$	—	$	—		$	2,710
	Money market fund	9,593		—		—			9,593
	Total	$	12,303	$	—	$	—		$	12,303

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Summary of financial instruments measured at fair value on a recurring basis	'
	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	1,133		$	—	$	—	$	1,133
	Money market funds (1)	31,417			—		—		31,417
	Domestic corporate debt securities (2)	—			5,381		—		5,381
	Domestic corporate commercial paper (2)	—			10,440		—		10,440
	Total	$	32,550		$	15,821	$	—	$	48,371
	Marketable securities:
	Domestic corporate debt securities (2)	—			22,152		—		22,152
	Domestic corporate commercial paper (2)	—			8,498		—		8,498
	Total	$	—		$	30,650	$	—	$	30,650
		December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash	$	2,710		$	—	$	—	$	2,710
	Money market funds (1)	9,593			—		—		9,593
		$	12,303		$	—	$	—	$	12,303
	Liabilities
	Warrant liability (3)	$	—		$	—	$	1,945	$	1,945
	Stock liability (3)	—			—		5,328		5,328
		$	—		$	—	$	7,273	$	7,273
	(1)              Fair value is based upon quoted market prices.
	(2)              Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.  Inputs are obtained from various sources, including market participants, dealers and brokers.
	(3)              Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below.  Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.
Roll-forward of fair value of assets determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2013	$	—
	Issuance of shares of Series A-6 - prepayment	1,220
	Nordic amendment	(1,220		)
	Balance at June 30, 2014	$	—
Roll-forward of fair value of liabilities determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2013	$	7,273
	Issuance of shares of Series A-6	(8,889		)
	Additions — accrued shares of Series A-6	2,717
	Additions — warrants	1,511
	Change in fair value	505
	Warrant liability reclassified to equity	(3,117		)
	Balance at June 30, 2014	$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Stock-Based Compensation	'
Summary of stock option activity	'
	A summary of stock option activity during the six months ended June 30, 2014 is as follows (in thousands, except for per share amounts):
				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2013	1,667		$	7.05
	Granted	1,799		7.9
	Exercised	—		—
	Forfeited	(586	)	8.65
	Expired	(1	)	3.42
	Options outstanding at June 30, 2014	2,879		$	7.26	8.28	$	64,451
	Options exercisable at June 30, 2014	1,363		$	6.51	6.76	$	31,520
	Options vested or expected to vest at June 30, 2014	2,795		$	7.24	8.24	$	62,607

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Net Loss Per Share	'
Schedule of basic and diluted net loss per share	'
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Numerator:
	Net loss	$	(12,609	)	$	(19,512	)	$	(27,097	)	$	(27,817	)
	Accretion of Preferred Stock	(4,031		)	(4,368		)	(9,000		)	(7,950		)
	Loss attributable to common stockholders - basic and diluted	$	(16,640	)	$	(23,880	)	$	(36,097	)	$	(35,767	)
	Denominator:
	Weighted-average number of common shares used in loss per share - basic and diluted (1)	7,500,148			381,525			3,962,559			380,942
	Loss per share - basic and diluted	$	(2.22	)	$	(62.59	)	$	(9.11	)	$	(93.89	)
	(1)              Common shares adjusted for 2.28:1 stock split that was affected April 24, 2014.
Schedule of potentially dilutive securities excluded from the computation of diluted weighted-average shares outstanding	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Convertible preferred stock	7,043,931		7,041,888		7,779,266		6,452,734
	Options to purchase common stock	2,621,820		1,706,787		2,373,083		1,708,460
	Warrants	1,311,356		589,328		1,161,639		303,751

Organization_Details

Organization (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization	'	'
Accumulated deficit	$308,856	$277,301

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Details) (USD $)	0 Months Ended			1 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 25, 2014	Jun. 11, 2014	Apr. 24, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 11, 2014
						Common Stock	Common Stock
Basis of Presentation and Significant Accounting Policies	'	'	'	'	'	'	'
Common Stock issued under initial public offering (in shares)	'	6,500,000	'	'	'	7,012,744	'
Share issue price (in dollars per share)	'	$8	'	'	'	'	'
Conversion of convertible preferred stock into common stock (in shares)	'	19,465,132	'	'	'	22,327,786	'
Number of shares of common stock issued in satisfaction of accumulated dividends accrued on the preferred stock	'	2,862,654	'	'	'	'	'
Initial public offering	'	'	'	'	'	'	'
Warrants issued for purchase of shares of common stock (in shares)	'	'	'	'	'	'	149,452
Options exercised by underwriters (in shares)	512,744	'	'	'	'	'	'
Aggregate proceeds received, net of underwriting discounts and commissions and offering costs	'	'	'	$50.20	'	'	'
Common stock, shares authorized	'	'	'	200,000,000	100,000,000	'	'
Reverse stock-split ratio	'	'	2.28	'	'	'	'

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities	'	'
Research costs - Nordic	$14,083	$17,998
Research costs - other	2,327	1,599
Payroll and employee benefits	932	1,005
Professional fees	2,208	426
Vacation	119	69
Interest on notes payable	205	852
Other	21	58
Total accrued expenses and other current liabilities	$19,895	$22,007

Loan_and_Security_Agreement_De

Loan and Security Agreement (Details) (USD $)	0 Months Ended				0 Months Ended	6 Months Ended		0 Months Ended		0 Months Ended
	Jun. 11, 2014	30-May-14	Jun. 30, 2014	Dec. 31, 2013	30-May-14	Jun. 30, 2014	Feb. 14, 2014	Jun. 11, 2014	Feb. 14, 2014	30-May-14	30-May-14
					Series B-2	Series B-2	Series B-2	Series B-2	Series B-2	Initial Term Loan	Second Term Loan
								Maximum	Maximum	item
Loan and Security Agreement	'	'	'	'	'	'	'	'	'	'	'
Aggregate principal amount	'	'	'	'	'	'	'	'	'	$21,000,000	'
Number of payments of principal and interest payable monthly	'	'	'	'	'	'	'	'	'	36	'
Minimum aggregate net cash proceeds required to be received to make interest only payments	'	'	'	'	'	'	'	'	'	65,000,000	'
Number of interest and principal payments to be made if minimum required aggregate net cash proceeds are received	'	'	'	'	'	'	'	'	'	30	'
Future principal payments under the New Credit Facility	'	'	'	'	'	'	'	'	'	'	'
2015	'	'	3,500,000	'	'	'	'	'	'	'	'
2016	'	'	7,000,000	'	'	'	'	'	'	'	'
2017	'	'	7,000,000	'	'	'	'	'	'	'	'
2018	'	'	3,500,000	'	'	'	'	'	'	'	'
Total	'	'	21,000,000	'	'	'	'	'	'	'	'
Additional term loan that can be requested if threshold of IPO is met	'	'	'	'	'	'	'	'	'	'	9,000,000
Threshold net cash proceed as prerequisite to request additional term loan	'	'	'	'	'	'	'	'	'	'	65,000,000
Basis spread (as a percent)	'	'	'	'	'	'	'	'	'	9.85%	'
Variable interest rate, description	'	'	'	'	'	'	'	'	'	'one-month LIBOR	'
Proceeds used to repay existing credit facility	'	9,300,000	'	'	'	'	'	'	'	'	'
Number of shares that can be purchased for warrants issued	'	'	'	'	10,258	'	'	'	718,201	'	'
Exercise price of warrant (in dollars per share)	'	'	'	'	$61.42	'	$14.00	'	'	'	'
Share issue price (in dollars per share)	$8	'	'	'	$8	'	'	'	'	'	'
Conversion of convertible preferred stock, and associated accumulated dividends into common stock (in shares)	19,465,132	'	'	'	'	-448,060	'	'	'	'	'
Conversion of convertible preferred stock, and associated accumulated dividends into common stock (in shares)	'	'	'	'	'	'	'	78,760	'	'	'
Expiration term of warrants	'	'	'	'	'5 years	'	'	'	'	'	'
Fair value of warrants issued	'	'	'	1,945,000	'	'	'	'	'	300,000	'
Payment of facility fees to lender	'	'	'	'	'	'	'	'	'	300,000	'
Payment of reimbursed costs to lender	'	'	'	'	'	'	'	'	'	$100,000	'
Debt discount amortization period	'	'	'	'	'	'	'	'	'	'48 months	'

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)	2 Months Ended	6 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Jun. 30, 2014	Jun. 11, 2014	Jun. 06, 2014	30-May-14	Feb. 14, 2014	Dec. 31, 2013
		item
Series B	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	701,235
Number of shares authorized	'	0	'	'	'	'	980,000
Purchase price per share of convertible preferred stock (in dollars per share)	'	$61.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	'	'	$14.00	'	'	'
Preferred Stock conversion ratio (in shares)	'	'	'	4.386	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'	'	'	'
Accrued dividend	'	'	'	$3.90	'	'	'
Number of times of original purchase price, which will be paid to the preferred stockholders	'	200.00%	'	'	'	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'	'	'	'
Series B | Minimum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	'	70.00%	'	'	'	'	'
Series B-2	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	448,060	'	'	'	'	'	0
Number of shares authorized	'	0	'	'	'	'	655,000
Warrants issued for purchase of shares of common stock (in shares)	'	'	'	'	10,258	'	'
Exercise price of warrants (in dollars per unit)	'	'	'	'	$61.42	$14.00	'
Proceeds from issuance of shares	27.5	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$61.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	'	'	$8	'	'	'
Preferred Stock conversion ratio (in shares)	'	'	'	7.678	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'	'	'	'
Accrued dividend	'	'	0.7	'	'	'	'
Number of times of original purchase price, which will be paid to the preferred stockholders	'	150.00%	'	'	'	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'	'	'	'
Series B-2 | Minimum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	'	70.00%	'	'	'	'	'
Series B-2 | Maximum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Amount to be raised	'	'	'	'	'	40.2	'
Number of shares authorized	'	'	'	'	'	655,000	'
Warrants issued for purchase of shares of common stock (in shares)	'	'	'	'	'	718,201	'
Warrants issued for purchase of shares of common stock (in shares)	491,293	'	'	'	'	'	'
Series A Convertible Preferred Stock	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'	'	'	'
Series A-1	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	939,612
Number of shares authorized	'	0	'	'	'	'	1,000,000
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	$16.97	'	'	'	'	'
Original conversion price per share (in dollars per share)	'	$18.56	'	'	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Preferred Stock conversion ratio (in shares)	'	4.798	'	'	'	'	'
Accrued dividend	'	'	'	18.1	'	'	'
Members of the Company's Board of Directors that can be elected by preferred stockholders	'	2	'	'	'	'	'
Series A-1 | After payment in full of required Series B and B-2 preferred dividends	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'	'	'	'
Series A-1 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B and Series B-2 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Series A-1 | Minimum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	'	70.00%	'	'	'	'	'
Series A-2	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	983,208
Number of shares authorized	'	0	'	'	'	'	983,213
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	$16.97	'	'	'	'	'
Original conversion price per share (in dollars per share)	'	$18.56	'	'	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Preferred Stock conversion ratio (in shares)	'	4.798	'	'	'	'	'
Accrued dividend	'	'	'	21.2	'	'	'
Series A-2 | After payment in full of required Series B, Series B-2 and A-1 preferred dividends	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'	'	'	'
Series A-2 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, SeriesB-2 and Series A-1 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Series A-2 | Minimum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	'	70.00%	'	'	'	'	'
Series A-3	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	142,227
Number of shares authorized	'	0	'	'	'	'	142,230
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	$16.97	'	'	'	'	'
Original conversion price per share (in dollars per share)	'	$18.56	'	'	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Preferred Stock conversion ratio (in shares)	'	4.798	'	'	'	'	'
Accrued dividend	'	'	'	$3.10	'	'	'
Series A-3 | After payment in full of required Series B, Series B-2, Series A-1 and A-2 preferred dividends	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'	'	'	'
Series A-3 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Series A-3 | Minimum	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	'	70.00%	'	'	'	'	'
Series A-4	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	3,998
Number of shares authorized	'	0	'	'	'	'	4,000
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	'	'	$18.56	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Series A-4 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1, Series A-2 , Series A-3, Series A-5 and Series A-6 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Series A-5	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	6,443
Number of shares authorized	'	0	'	'	'	'	7,000
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	'	'	$18.56	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Series A-5 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Series A-6	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Number of shares issued	'	0	'	'	'	'	496,111
Number of shares authorized	'	0	'	'	'	'	800,000
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'
Conversion price per share (in dollars per share)	'	'	'	$18.56	'	'	'
Original preferred stock conversion ratio (in shares)	'	4.386	'	'	'	'	'
Series A-6 | Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'	'	'	'
Convertible Preferred Stock	'	'	'	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	'	$81.42	'	'	'	'	'

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
	item	item
Available-for-sale marketable securities	'	'	'	'
Cash and cash equivalents, Amortized Cost Value	$48,371,000	$12,303,000	$24,824,000	$18,653,000
Cash and cash equivalents, Gross Unrealized Gains	1,000	'	'	'
Cash and cash equivalents, Gross Unrealized Losses	-1,000	'	'	'
Cash and cash equivalents, Fair Value	48,371,000	'	'	'
Marketable securities, Amortized Cost Value	30,649,000	'	'	'
Marketable securities, Gross Unrealized Gains	6,000	'	'	'
Marketable securities, Gross Unrealized Losses	-5,000	'	'	'
Marketable securities, Fair Value	30,650,000	'	'	'
Debt securities held in an unrealized loss position for more than 12 months	0	0	'	'
Debt securities held in an unrealized loss position for less than 12 months	13	0	'	'
Fair value of debt securities in an unrealized position for less than 12 months	27,500,000	'	'	'
Maximum	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Unrealized loss on debt securities in an unrealized loss position for less than 12 months	5,000	'	'	'
Marketable securities, contractual term to maturity	'1 year	'	'	'
Domestic corporate debt securities	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Marketable securities, Amortized Cost Value	22,157,000	'	'	'
Marketable securities, Gross Unrealized Losses	-5,000	'	'	'
Marketable securities, Fair Value	22,152,000	'	'	'
Domestic corporate commercial paper	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Marketable securities, Amortized Cost Value	8,492,000	'	'	'
Marketable securities, Gross Unrealized Gains	6,000	'	'	'
Marketable securities, Fair Value	8,498,000	'	'	'
Cash	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Cash and cash equivalents, Amortized Cost Value	1,133,000	2,710,000	'	'
Cash and cash equivalents, Fair Value	1,133,000	2,710,000	'	'
Money market funds	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Cash and cash equivalents, Amortized Cost Value	31,417,000	9,593,000	'	'
Cash and cash equivalents, Fair Value	31,417,000	9,593,000	'	'
Domestic corporate debt securities	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Cash and cash equivalents, Amortized Cost Value	5,382,000	'	'	'
Cash and cash equivalents, Gross Unrealized Losses	-1,000	'	'	'
Cash and cash equivalents, Fair Value	5,381,000	'	'	'
Domestic corporate commercial paper	'	'	'	'
Available-for-sale marketable securities	'	'	'	'
Cash and cash equivalents, Amortized Cost Value	10,439,000	'	'	'
Cash and cash equivalents, Gross Unrealized Gains	1,000	'	'	'
Cash and cash equivalents, Fair Value	$10,440,000	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 06, 2014	Dec. 31, 2013
	item
Assets	'	'	'
Cash and Cash equivalents:	$48,371,000	'	'
Liabilities	'	'	'
Warrant liability	'	'	1,945,000
Number of work statements executed with the Nordic Work Statements	3	'	'
Conversion of right to receive shares of Series A-6 to the right to receive total potential cash payments upon completion of IPO	'	4,300,000	'
Cash	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	1,133,000	'	2,710,000
Money market funds	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	31,417,000	'	9,593,000
Domestic corporate debt securities	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	5,381,000	'	'
Domestic corporate commercial paper	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	10,440,000	'	'
Recurring basis | Level 1	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	32,550,000	'	12,303,000
Recurring basis | Level 1 | Cash	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	1,133,000	'	2,710,000
Recurring basis | Level 1 | Money market funds	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	31,417,000	'	9,593,000
Recurring basis | Level 2	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	15,821,000	'	'
Marketable securities	30,650,000	'	'
Recurring basis | Level 2 | Domestic corporate debt securities	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	5,381,000	'	'
Marketable securities	22,152,000	'	'
Recurring basis | Level 2 | Domestic corporate commercial paper	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	10,440,000	'	'
Marketable securities	8,498,000	'	'
Recurring basis | Level 3	'	'	'
Liabilities	'	'	'
Warrant liability	'	'	1,945,000
Stock liability	'	'	5,328,000
Total liabilities carried at fair value	'	'	7,273,000
Recurring basis | Estimated Fair Value	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	48,371,000	'	12,303,000
Marketable securities	30,650,000	'	'
Liabilities	'	'	'
Warrant liability	'	'	1,945,000
Stock liability	'	'	5,328,000
Total liabilities carried at fair value	'	'	7,273,000
Recurring basis | Estimated Fair Value | Cash	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	1,133,000	'	2,710,000
Recurring basis | Estimated Fair Value | Money market funds	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	31,417,000	'	9,593,000
Recurring basis | Estimated Fair Value | Domestic corporate debt securities	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	5,381,000	'	'
Recurring basis | Estimated Fair Value | Domestic corporate commercial paper	'	'	'
Assets	'	'	'
Cash and Cash equivalents:	10,440,000	'	'
Recurring basis | Estimated Fair Value | Domestic corporate debt securities	'	'	'
Assets	'	'	'
Marketable securities	22,152,000	'	'
Recurring basis | Estimated Fair Value | Domestic corporate commercial paper	'	'	'
Assets	'	'	'
Marketable securities	$8,498,000	'	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Roll-forward of the fair value of the assets, where fair value is determined by Level 3 inputs	'
Issuance of shares of Series A-6 - prepayment	$1,220
Conversion of amount receivable in shares of series A-6 stock to amount payable in cash under the Nordic amendment	-1,220
Roll-forward of the fair value of the liabilities, where fair value is determined by Level 3 inputs	'
Balance at the beginning of the period	7,273
Issuance of shares of Series A-6	-8,889
Additions - accrued shares of Series A-6	2,717
Additions - warrants	1,511
Change in fair value	505
Warrants liability reclassified to equity	($3,117)

License_Agreements_Details

License Agreements (Details)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2005

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

USD ($)

USD ($)

USD ($)

USD ($)

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Minimum

Minimum

Maximum

Maximum

Sublicense Agreement

USD ($)

EUR (€)

USD ($)

EUR (€)

Minimum

License Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonrefundable, non-creditable payment

'

'

'

'

'

'

'

'

$250,000

'

'

'

'

'

Additional payments to be made upon achievement of certain development and commercialization milestones

'

'

'

'

'

'

'

'

'

13,700,000

10,000,000

49,300,000

36,000,000

'

Royalty rate (as a percent)

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

Period after the date of the first commercial sale of the product for license expiration

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'10 years

Amount recorded in research and development expense

$10,618,000

$16,240,000

$20,335,000

$33,527,000

$200,000

$100,000

$200,000

$100,000

'

'

'

'

'

'

Research_Agreements_Details

Research Agreements (Details)

0 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

Jun. 11, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2011

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2014

17-May-11

Mar. 29, 2011

17-May-11

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 06, 2013

Dec. 06, 2013

Oct. 31, 2012

Oct. 31, 2012

USD ($)

USD ($)

USD ($)

USD ($)

Series A-5

Series A-5

Series A-6

Series A-6

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

USD ($)

USD ($)

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Pass-through costs

Pass-through costs

Pass-through costs

Pass-through costs

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

NB-3 Amendment

NB-3 Amendment

NB-3 Amendment

NB-3 Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Fourth Amendment

Fourth Amendment

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Letter of Intent

Letter of Intent

Letter of Intent

Letter of Intent

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

Nordic

USD ($)

USD ($)

USD ($)

USD ($)

item

USD ($)

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Nordic

Nordic

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Nordic

Nordic

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Extension Clinical Study

USD ($)

EUR (€)

Maximum

Maximum

Series A-6

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

item

United States

United States

United States

India

India

India

Per patient costs for enrolled patients

item

USD ($)

EUR (€)

Maximum

Maximum

Nordic

Nordic

Series A-6

Series A-6

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

item

USD ($)

EUR (€)

Maximum

USD ($)

EUR (€)

Maximum

Maximum

Series A-6

Series A-6

item

Maximum

Maximum

item

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

Maximum

USD ($)

USD ($)

Series A-5

Series A-5

Series A-5

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

EUR (€)

item

USD ($)

item

USD ($)

EUR (€)

Former Operating Company

Maximum

Maximum

Maximum

Maximum

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Research Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries where study was to be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional countries where study will be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional study sites

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of euro-denominated installments

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of U.S dollar-denominated installments

'

'

'

'

'

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of euro-denominated payments required over the course of Clinical Trial

'

'

'

'

'

'

'

'

'

$56,300,000

€ 41,200,000

$4,900,000

€ 3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,300,000

€ 7,500,000

$4,100,000

€ 3,000,000

'

'

'

'

$1,600,000

€ 1,200,000

'

$982,531

€ 717,700

'

'

'

'

$5,100,000

€ 3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of U.S. dollar-denominated payments required over the course of Clinical Trial

'

'

'

'

'

'

'

'

'

3,200,000

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

527,740

'

'

'

'

'

143,369

'

'

289,663

'

'

'

'

'

205,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of shares agreed to be purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

371,864

'

'

'

'

'

'

'

'

'

'

Purchase price per share of convertible preferred stock (in dollars per share)

'

'

'

'

'

$81.42

'

$81.42

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.14

'

'

'

'

'

'

'

'

'

'

'

Additional term provided for standard-of-care treatment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'18 months

'

'

Dividend declared (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

186,847

186,847

'

'

'

'

'

32,215

'

'

'

'

'

'

Stock dividends declared

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

'

'

'

'

'

0

6,443

0

496,111

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

186,847

186,847

'

'

'

'

'

'

'

'

'

'

'

'

Payments owed to be changed from the right to receive stock to the right to receive cash payment, if an IPO occurs prior to May 31, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of equal monthly installments for cash payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of equal monthly installments for cash payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

430,000

'

'

'

'

'

'

'

'

'

'

'

'

Shares sold

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,430

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

525,154

'

'

'

'

'

'

'

'

'

'

'

Number of shares exchanged in the Merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,443

'

'

'

'

'

'

'

'

'

Aggregate value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,400,000

36,800,000

'

10,300,000

7,500,000

'

'

'

'

Aggregate U.S. dollar value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

527,740

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

Number of shares due to the counter party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,215

'

'

'

'

'

'

Number of shares due to the counter party after conversion of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

141,294

'

'

'

'

'

'

Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

11,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of initial payments for Euro-denominated installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

222,573

1,100,000

806,468

Maximum aggregate amount of additional payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of additional performance incentive payable to every specified patient

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of patients to whom additional performance incentive is payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period for which research and development expense is recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 months

'

'

'9 months

'

'

'

'9 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'19 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

'

10,618,000

16,240,000

20,335,000

33,527,000

'

'

'

'

'

'

'

'

'

'

'

200,000

900,000

500,000

2,000,000

'

'

2,400,000

8,800,000

6,900,000

17,900,000

1,700,000

'

3,400,000

2,900,000

800,000

5,400,000

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in amount of euro-denominated payments required over the course of clinical study

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16,347

€ 11,941

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Stock option, USD $)	3 Months Ended	6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
Stock option	'	'
Summary of stock option activity - Shares	'	'
Options outstanding at the beginning of the period (in shares)	'	1,667
Granted (in shares)	'	1,799
Forfeited (in shares)	'	-586
Expired (in shares)	'	-1
Options outstanding at the end of the period (in shares)	28,790	28,790
Options exercisable at the end of the period (in shares)	1,363	1,363
Options vested and expected to vest at the end of the period (in shares)	2,795	2,795
Summary of stock option activity - Weighted-Average Exercise Price (in dollars per share)	'	'
Options outstanding at the beginning of the period (in dollars per share)	'	$7.05
Granted (in dollars per share)	'	$7.90
Forfeited (in dollars per share)	'	$8.65
Expired (in dollars per share)	'	$3.42
Options outstanding at the end of the period (in dollars per share)	$7.26	$7.26
Options exercisable at the end of the period (in dollars per share)	$6.51	$6.51
Options vested and expected to vest at the end of the period (in dollars per share)	$7.24	$7.24
Weighted-Average Contractual Life (In Years)	'	'
Options outstanding at the end of the period	'	'8 years 3 months 11 days
Options exercisable at the end of the period	'	'6 years 9 months 4 days
Options vested and expected to vest at the end of the period	'	'8 years 2 months 26 days
Aggregate Intrinsic Value	'	'
Options outstanding at the end of the period (in dollars)	$64,451,000	$64,451,000
Options exercisable at the end of the period (in dollars)	31,520,000	31,520,000
Options vested and expected to vest at the end of the period (in dollars)	62,607,000	62,607,000
Additional disclosures	'	'
Weighted-average grant-date fair value (in dollars per share)	$4.60	$4.61
Total grant date fair value of stock options vested	'	$1,400,000

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Summary of stock-based compensation expense	'
Total unrecognized compensation expense	$6.50
Weighted average period over which unrecognized compensation is expected to be recognized	'3 years

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 24, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'	'
Net loss	'	($12,609)	($19,512)	($27,097)	($27,817)
Accretion of Preferred Stock	'	-4,031	-4,368	-9,000	-7,950
Loss attributable to common stockholders - basic and diluted	'	($16,640)	($23,880)	($36,097)	($35,767)
Denominator:	'	'	'	'	'
Weighted-average number of common shares used in loss per share - basic and diluted	'	7,500,148	381,525	3,962,559	380,942
Loss per share - basic and diluted (in dollars per share)	'	($2.22)	($62.59)	($9.11)	($93.89)
Reverse stock-split ratio	2.28	'	'	'	'

Net_Loss_Per_Share_Details_2

Net Loss Per Share (Details 2)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Convertible preferred stock	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	7,043,931	7,041,888	7,779,266	6,452,734
Options to purchase common stock	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	2,621,820	1,706,787	2,373,083	1,708,460
Warrants	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	1,311,356	589,328	1,161,639	303,751

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event)	30-May-14	Jul. 22, 2014	Jul. 22, 2014	Jul. 10, 2014	Jul. 10, 2014	Jul. 10, 2014	Jul. 10, 2014	30-May-14	Jul. 10, 2014	Jul. 10, 2014
	USD ($)	Sixth Amendment	Sixth Amendment	New Tranche B Warrants	New Tranche B2 Warrants	New Tranche B2 Warrants	Term Loan	Term Loan	Term Loan B	Term Loan C
		USD ($)	EUR (€)	USD ($)	Solar	Oxford	USD ($)	USD ($)	USD ($)	USD ($)
Subsequent Events	'	'	'	'	'	'	'	'	'	'
Aggregate principal amount	$30,000,000	'	'	'	'	'	'	'	'	'
Amount drawn	'	'	'	'	'	'	4,000,000	21,000,000	'	'
Term loan that can be requested if threshold of initial public offering is met	'	'	'	'	'	'	'	'	9,000,000	'
Threshold net cash proceed as prerequisite to request term loan	'	'	'	'	'	'	'	'	65,000,000	'
Additional term loan aggregate principal amount to be provided upon the closing of the First Amendment	'	'	'	'	'	'	'	'	4,000,000	'
Additional term loan aggregate principal amount to be provided upon fulfillment of specific conditions	'	'	'	'	'	'	'	'	'	5,000,000
Aggregate net proceeds to be raised after closing of the First Amendment, for providing additional term loan	'	'	'	'	'	'	'	'	'	13,000,000
Number of shares that can be purchased for warrants issued	'	'	'	'	4,706	4,706	'	'	'	'
Exercise price of warrants (in dollars per unit)	'	'	'	$12.75	'	'	'	'	'	'
Amount of euro-denominated payments required over the course of Clinical Trial	'	$1,100,000	€ 833,957	'	'	'	'	'	'	'